생체 동일 호르몬 시장 조사 보고서 - 2032년까지 예측
| CAGR (2025 - 2035) | 5.7% |
The Bioidentical Hormones Market is projected to reach approximately 4.362 USD Billion by 2035.
In 2024, the Bioidentical Hormones Market was valued at 2.37 USD Billion.
The expected CAGR for the Bioidentical Hormones Market during the forecast period 2025 - 2035 is 5.7%.
Key players in the Bioidentical Hormones Market include AbbVie, Bayer, Thermo Fisher Scientific, Mylan, HRT, BioTE Medical, SottoPelle, Compounding Pharmacy of America, and Women's Health Network.
The estimated market values for Estrogens range from 0.95 to 1.75 USD Billion.
Tablets and Capsules are valued between 0.75 and 1.4 USD Billion, making them a leading product type compared to others.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed endocrinology journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) - specifically the Division of Reproductive and Urologic Products and Pharmacy Compounding Advisory Committee, European Medicines Agency (EMA) - Committee for Medicinal Products for Human Use (CHMP), Drug Enforcement Administration (DEA) for controlled substance testosterone tracking, National Institute on Aging (NIA), North American Menopause Society (NAMS), Endocrine Society, American College of Obstetricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ASRM), International Menopause Society (IMS), American Thyroid Association, National Institutes of Health (NIH/NCBI/PubMed) for clinical efficacy meta-analyses, Centers for Medicare & Medicaid Services (CMS) for reimbursement coding analysis, CDC National Center for Health Statistics for menopause prevalence data, World Health Organization (WHO) Global Health Observatory for demographic aging trends, United Nations Demographic Yearbook for postmenopausal population projections, OECD Health Statistics for HRT utilization rates, Pharmacy Compounding Accreditation Board (PCAB) for 503A/503B facility data, National Association of Boards of Pharmacy (NABP) for regulatory compliance tracking, and national health ministry reports from key markets including India (CDSCO), Brazil (ANVISA), and Japan (PMDA). These sources were used to collect prescription statistics, FDA approval data (including BIJUVA and IMVEXXY pathways), clinical safety studies (WHI follow-up data), demographic menopause trends, and market landscape analysis for estrogen, progesterone, testosterone, thyroid hormones, and growth hormone segments.
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources comprised CEOs, VPs of Endocrinology Product Development, chiefs of Regulatory Affairs who specialized in 505(b)(2) pathways, and commercial directors from bioidentical hormone manufacturers, 503B outsourcing facilities, and hormone-specific compounding pharmacy networks. Board-certified endocrinologists, board-certified gynecologists who specialize in menopause management, age management medicine physicians, medical directors of anti-aging and wellness clinics, procurement leads from hospital pharmacy systems, and formulary decision-makers from specialty pharmacies were the demand-side sources.
Primary Respondent Breakdown:
By Designation: C-level Primaries (40%), Director Level (30%), Others (30%)
By Region: North America (40%), Europe (25%), Asia-Pacific (25%), Rest of World (10%)
Global market valuation was derived through revenue mapping and prescription volume analysis specific to bioidentical hormone therapies. The methodology included:
Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America, including FDA-approved pharmaceutical manufacturers and 503A/503B compounding facilities
Product mapping across oral capsules/tablets, transdermal creams/gels, subcutaneous injections, and implantable pellet categories
Analysis of reported and modeled annual revenues specific to bioidentical hormone portfolios (estradiol, progesterone, testosterone, compounded combinations)
Coverage of manufacturers representing 65-70% of global market share in 2024, with specific attention to distinction between commercial FDA-approved bioidenticals and compounded preparations
Extrapolation using bottom-up (menopausal female population + hypogonadal male population × treatment penetration rate × average treatment duration × ASP by country) and top-down (manufacturer revenue validation across public 10-K filings and private company estimates) approaches to derive segment-specific valuations for estrogen, progesterone, testosterone, and combination therapies
Adjustment for direct-to-consumer telemedicine channels and cash-pay wellness clinic volumes not captured in traditional pharmacy audit data
이 보고서의 무료 샘플을 받으려면 아래 양식을 작성하십시오
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thank you, this will be very helpful for OQS.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
